Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Ethical Considerations
2.2. Patient Population and Eligibility Criteria
2.3. Treatment Details
2.4. Patient Assessment and Study Endpoints
2.5. Statistical Analysis
3. Results
4. Discussion
4.1. Methodological Considerations
4.2. Main Findings and Available Evidence
4.3. Strengths and Limitations
4.4. Future Perspectives
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Liedberg, F.; Mariappan, P.; Gontero, P. EAU NMIBC Guideline Panel. Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel. Eur. Urol. Oncol. 2025, 8, 234–236. [Google Scholar] [CrossRef]
- Contieri, R.; Hurle, R.; Paciotti, M.; Casale, P.; Saita, A.; Porpiglia, F.; Fiori, C.; Barone, B.; Crocetto, F.; Lucarelli, G.; et al. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. Minerva Urol. Nephrol. 2023, 75, 180–187. [Google Scholar] [CrossRef]
- Siracusano, S.; Silvestri, T.; Bassi, S.; Porcaro, A.B.; Cerruto, M.A.; Talamini, R.; Artibani, W. Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can. J. Urol. 2018, 25, 9480–9485. [Google Scholar]
- Decaestecker, K.; Oosterlinck, W. Managing the adverse events of intravesical bacillus Calmette-Guérin therapy. Res. Rep. Urol. 2015, 7, 157–163. [Google Scholar]
- Ferro, M.; Del Giudice, F.; Carrieri, G.; Busetto, G.M.; Cormio, L.; Hurle, R.; Contieri, R.; Arcaniolo, D.; Sciarra, A.; Maggi, M.; et al. The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis. Cancers 2021, 13, 5276. [Google Scholar] [CrossRef]
- Del Giudice, F.; Asero, V.; Bologna, E.; Scornajenghi, C.M.; Carino, D.; Dolci, V.; Viscuso, P.; Salciccia, S.; Sciarra, A.; D’andrea, D.; et al. Efficacy of different Bacillus of Calmette-Guérin (BCG) strains on recurrence rates among intermediate/high-risk non-muscle invasive bladder cancers (NMIBCs): Single-arm study systematic review, cumulative and network meta-analysis. Cancers 2023, 15, 1937. [Google Scholar] [CrossRef]
- Capece, M.; Spirito, L.; La Rocca, R.; Napolitano, L.; Buonopane, R.; Di Meo, S.; Sodo, M.; Bracale, U.; Longo, N.; Palmieri, A.; et al. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC): A retrospective analysis. Arch. Ital. Urol. Androl. 2020, 92, 17–20. [Google Scholar] [CrossRef]
- Busetto, G.M.; Finati, M.; Chirico, M.; Cinelli, F.; D’aLtilia, N.; Falagario, U.G.; Sanguedolce, F.; Del Giudice, F.; De Berardinis, E.; Ferro, M.; et al. Conservative treatment for high-risk NMIBC failing BCG treatment: Who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle? World J. Urol. 2023, 41, 1329–1335. [Google Scholar] [CrossRef]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Pareek, T.; Parmar, K.; Sharma, A.P.; Kumar, S. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Urol. Int. 2022, 106, 784–790. [Google Scholar] [CrossRef]
- Wang, C.; Jin, W.; Ma, X.; Dong, Z. The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia. Front. Oncol. 2023, 12, 1101830. [Google Scholar] [CrossRef]
- Li, X.; Ma, X.; Tang, L.; Wang, B.; Chen, L.; Zhang, F.; Zhang, X. Prognostic value of neutrophil-to-lymphocyte ratio in urothelial carcinoma of the upper urinary tract and bladder: A systematic review and meta-analysis. Oncotarget 2017, 8, 62681–62692. [Google Scholar] [CrossRef]
- Bourlotos, G.; Baigent, W.; Hong, M.; Plagakis, S.; Grundy, L. BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies. Front. Neurosci. 2024, 17, 1327053. [Google Scholar] [CrossRef]
- Crocetto, F.; Amicuzzi, U.; Musone, M.; Magliocchetti, M.; Di Lieto, D.; Tammaro, S.; Pastore, A.L.; Fuschi, A.; Falabella, R.; Ferro, M.; et al. Liquid Biopsy: Current advancements in clinical practice for bladder cancer. J. Liq. Biopsy 2025, 9, 100310. [Google Scholar] [CrossRef]
- Simons, M.P.; O’DOnnell, M.A.; Griffith, T.S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. Semin. Orig. Investig. 2008, 26, 341–345. [Google Scholar] [CrossRef]
- Zahorec, R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl. Med J. 2021, 122, 474–488. [Google Scholar] [CrossRef]
- van der Heijden, A.G.; Bruins, H.M.; Carrion, A.; Cathomas, R.; Compérat, E.; Dimitropoulos, K.; Efstathiou, J.A.; Fietkau, R.; Kailavasan, M.; Lorch, A.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. Eur. Urol. 2025, 87, 582–600. [Google Scholar] [CrossRef]
- Khoury, S.; Denis, L. International consultation on benign prostatic hyperplasia. Prog. Clin. Biol. Res. 1994, 386, 617–624. [Google Scholar]
- Barry, M.J.; Williford, W.O.; Chang, Y.; Machi, M.; Jones, K.M.; Walker-Corkery, E.; Lepor, H. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J. Urol. 1995, 154, 1770–1774. [Google Scholar] [CrossRef]
- González-Padilla, D.A.; González-Díaz, A.; Guerrero-Ramos, F.; Rodríguez-Serrano, A.; García-Jarabo, E.; Corona-Lapuerta, M.; Rodríguez-Antolín, A.; Villacampa-Aubá, F. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. Urol. Oncol. Semin. Orig. Investig. 2021, 39, 76.e9–76.e14. [Google Scholar] [CrossRef]
- Bilgic, D.; Surucu, S.G.; Beji, N.K.; Yalcin, O. Sexual function and urinary incontinence complaints and other urinary tract symptoms of perimenopausal Turkish women. Psychol. Health Med. 2019, 24, 1111–1122. [Google Scholar] [CrossRef]
- Ferro, M.; Tătaru, O.S.; Musi, G.; Lucarelli, G.; Abu Farhan, A.R.; Cantiello, F.; Damiano, R.; Hurle, R.; Contieri, R.; Busetto, G.M.; et al. Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical Bacillus Calmette–Guerin immunotherapy. Diagnostics 2022, 12, 586. [Google Scholar] [CrossRef]
- Grossmann, N.C.; Schuettfort, V.M.; Pradere, B.; Rajwa, P.; Quhal, F.; Mostafaei, H.; Laukhtina, E.; Mori, K.; Motlagh, R.S.; Aydh, A.; et al. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urol. Oncol. Semin. Orig. Investig. 2022, 40, 106.e11–106.e19. [Google Scholar] [CrossRef]
- Sylvester, R.J.; Brausi, M.A.; Kirkels, W.J.; Hoeltl, W.; Da Silva, F.C.; Powell, P.H.; Prescott, S.; Kirkali, Z.; van de Beek, C.; Gorlia, T.; et al. EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 2010, 57, 766–773. [Google Scholar]
- Oddens, J.; Brausi, M.; Sylvester, R.; Bono, A.; van de Beek, C.; van Andel, G.; Gontero, P.; Hoeltl, W.; Turkeri, L.; Marreaud, S.; et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 2013, 63, 462–472. [Google Scholar] [CrossRef]
- Yang, X.; Toh, Q.; Huang, H.; Sng, L.; Tan, T.; Ng, L. Intravesical Bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution. Singap. Med J. 2022, 63, 325–329. [Google Scholar] [CrossRef]
- Tammaro, S.; Arcaniolo, D.; Spirito, L.; Bottone, F.; Quattrone, C.; Stizzo, M.; Terribile, M.; Balsamo, R.; Napolitano, L.; Crocetto, F.; et al. Top researchers in andrology: A bibliometric and demographic analysis of the last 7 years. J. Men’s Health 2024, 20, 56–62. [Google Scholar]
- Templeton, A.J.; Mcnamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106, dju124. [Google Scholar] [CrossRef]
- Ferro, M.; Barone, B.; Crocetto, F.; Lucarelli, G.; Busetto, G.M.; Del Giudice, F.; Maggi, M.; Crocerossa, F.; Cantiello, F.; Damiano, R.; et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol. Oncol. Semin. Orig. Investig. 2022, 40, 490. [Google Scholar] [CrossRef]
- Grabe-Heyne, K.; Henne, C.; Mariappan, P.; Geiges, G.; Pöhlmann, J.; Pollock, R.F. Intermediate and high-risk non-muscle-invasive bladder cancer: An overview of epidemiology, burden, and unmet needs. Front. Oncol. 2023, 13, 1170124. [Google Scholar] [CrossRef]
Parameter | Total (n = 96) | NLR < 3 (n = 62) | NLR ≥ 3 (n = 34) | p-Value |
---|---|---|---|---|
Age, years Median [IQR] | 71 [68–75] | 72 [69–76] | 70 [67–73] | 0.07 |
BMI, kg/m2 Median [IQR] | 26.3 [24.1–28.8] | 26.1 [24.0–28.5] | 26.8 [24.3–29.2] | 0.29 |
Smoking, n (%) | 19 (19.8) | 11 (17.7) | 8 (23.5) | 0.49 |
Hypertension, n (%) | 56 (58.3) | 36 (58.1) | 20 (58.8) | 0.94 |
Diabetes, n (%) | 18 (18.8) | 11 (17.7) | 7 (20.6) | 0.72 |
BPH medications, n (%) | 71 (74.0) | 44 (71.0) | 27 (79.4) | 0.36 |
Hb levels, g/dL Mean (SD) | 11.9 (1.7) | 12.0 (1.6) | 11.7 (1.8) | 0.38 |
PLT, ×109/L Median [IQR] | 259 [241–279] | 262 [245–281] | 254 [236–275] | 0.08 |
NLR Median [IQR] | 2.6 [2.1–3.8] | 1.9 [1.6–2.2] | 4.1 [3.5–4.8] | <0.001 |
Tumor stage, n (%) Ta T1 | 27 (28.1) 69 (71.9) | 17 (27.4) 45 (72.6) | 10 (29.4) 24 (70.6) | 0.84 |
Tumor grade, n (%) High Low | 96 (100) 0 | 62 (100) 0 | 34 (100) 0 | NA |
Concomitant CIS *, n (%) | 29 (30.2) | 18 (29.0) | 11 (32.4) | 0.72 |
IPSS total, points Median [IQR] | 19 [17–22] | 19 [16–21] | 18 [17–23] | 0.06 |
IPSS-QoL, points Median [IQR] | 4 [3–4] | 3 [3–4] | 4 [3–5] | 0.09 |
Outcome | Total (n = 96) | NLR < 3 (n = 62) | NLR ≥ 3 (n = 34) | p-Value |
---|---|---|---|---|
IPSS total (baseline), Median [IQR] | 19 [17–22] | 19 [16–21] | 18 [17–23] | 0.06 |
IPSS total (8 weeks), Median [IQR] | 22 [19–25] | 21 [18–23] | 24 [21–27] | 0.02 |
Δtotal (8w—baseline), Median [IQR] | +3 [2–5] | +2 [1–3] | +5 [3–7] | 0.01 |
IPSS-QoL (baseline), Median [IQR] | 4 [3–4] | 3 [3–4] | 4 [3–5] | 0.09 |
IPSS-QoL (8 weeks), Median [IQR] | 5 [4–6] | 4 [3–5] | 5 [4–6] | 0.03 |
ΔQoL (8w—baseline), Median [IQR] | +1 [0–2] | +1 [0–1] | +1 [1–2] | 0.04 |
Outcome | Model | Predictor | β (95% CI) | p-Value |
---|---|---|---|---|
IPSS-QoL (primary) | Univariable | NLR ≥ 3 (vs. <3) | +0.74 (0.27 to 1.21) | 0.003 |
Univariable | NLR (per 1-unit increase) | +0.20 (0.05 to 0.34) | 0.008 | |
Multivariable 1 | NLR ≥ 3 (vs. <3) | +0.66 (0.14 to 1.17) | 0.014 | |
Multivariable 1 | NLR (per 1-unit increase) | +0.17 (0.03 to 0.31) | 0.019 | |
IPSS total (secondary) | Univariable | NLR ≥ 3 (vs. <3) | +2.20 (0.35 to 4.05) | 0.021 |
Univariable | NLR (per 1-unit increase) | +0.52 (0.02 to 1.03) | 0.042 | |
Multivariable 2 | NLR ≥ 3 (vs. <3) | +1.32 (−0.28 to 2.93) | 0.104 | |
Multivariable 2 | NLR (per 1-unit increase) | +0.34 (−0.06 to 0.74) | 0.096 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spirito, L.; Tammaro, S.; Coppola, P.; Manfredi, C.; Romano, L.; Sciorio, C.; Di Girolamo, A.; Napolitano, L.; Bottone, F.; Quattrone, C.; et al. Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study. J. Clin. Med. 2025, 14, 6908. https://doi.org/10.3390/jcm14196908
Spirito L, Tammaro S, Coppola P, Manfredi C, Romano L, Sciorio C, Di Girolamo A, Napolitano L, Bottone F, Quattrone C, et al. Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study. Journal of Clinical Medicine. 2025; 14(19):6908. https://doi.org/10.3390/jcm14196908
Chicago/Turabian StyleSpirito, Lorenzo, Simone Tammaro, Paola Coppola, Celeste Manfredi, Lorenzo Romano, Carmine Sciorio, Antonio Di Girolamo, Luigi Napolitano, Francesco Bottone, Carmelo Quattrone, and et al. 2025. "Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study" Journal of Clinical Medicine 14, no. 19: 6908. https://doi.org/10.3390/jcm14196908
APA StyleSpirito, L., Tammaro, S., Coppola, P., Manfredi, C., Romano, L., Sciorio, C., Di Girolamo, A., Napolitano, L., Bottone, F., Quattrone, C., Imperatore, V., Fusco, F., Arcaniolo, D., & De Sio, M. (2025). Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study. Journal of Clinical Medicine, 14(19), 6908. https://doi.org/10.3390/jcm14196908